BR112022009797A2 - Usos médicos de vaccinia vírus ankara modificado (mva) recombinante com coadjuvante de 4-1bbl - Google Patents
Usos médicos de vaccinia vírus ankara modificado (mva) recombinante com coadjuvante de 4-1bblInfo
- Publication number
- BR112022009797A2 BR112022009797A2 BR112022009797A BR112022009797A BR112022009797A2 BR 112022009797 A2 BR112022009797 A2 BR 112022009797A2 BR 112022009797 A BR112022009797 A BR 112022009797A BR 112022009797 A BR112022009797 A BR 112022009797A BR 112022009797 A2 BR112022009797 A2 BR 112022009797A2
- Authority
- BR
- Brazil
- Prior art keywords
- mva
- recombinant
- 1bbl
- vaccinia virus
- support
- Prior art date
Links
- 102000002627 4-1BB Ligand Human genes 0.000 title abstract 2
- 108010082808 4-1BB Ligand Proteins 0.000 title abstract 2
- 241000587120 Vaccinia virus Ankara Species 0.000 title 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 2
- 230000000139 costimulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19210369 | 2019-11-20 | ||
| EP20191226 | 2020-08-14 | ||
| EP20193706 | 2020-08-31 | ||
| PCT/EP2020/082888 WO2021099572A1 (en) | 2019-11-20 | 2020-11-20 | Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009797A2 true BR112022009797A2 (pt) | 2022-08-16 |
Family
ID=73455743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009797A BR112022009797A2 (pt) | 2019-11-20 | 2020-11-20 | Usos médicos de vaccinia vírus ankara modificado (mva) recombinante com coadjuvante de 4-1bbl |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230059344A1 (https=) |
| EP (1) | EP4061404A1 (https=) |
| JP (1) | JP7670705B2 (https=) |
| KR (1) | KR20220116191A (https=) |
| CN (1) | CN114929268A (https=) |
| AU (1) | AU2020388973A1 (https=) |
| BR (1) | BR112022009797A2 (https=) |
| CA (1) | CA3159666A1 (https=) |
| IL (1) | IL293012A (https=) |
| MX (1) | MX2022005601A (https=) |
| WO (1) | WO2021099572A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050790B (zh) * | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| US8691502B2 (en) * | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| MX367100B (es) * | 2012-02-17 | 2019-08-05 | The Children´S Hospital Of Philadelphia | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| CA2942501A1 (en) * | 2014-03-17 | 2015-09-24 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| WO2017120577A1 (en) | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| IL261321B2 (en) * | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| WO2017152042A2 (en) * | 2016-03-04 | 2017-09-08 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| CN111050790B (zh) | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| US20190345516A1 (en) * | 2018-03-12 | 2019-11-14 | Musc Foundation For Research Development | Methods for treating eye disease |
| CA3119503A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
-
2020
- 2020-11-20 IL IL293012A patent/IL293012A/en unknown
- 2020-11-20 EP EP20808119.0A patent/EP4061404A1/en active Pending
- 2020-11-20 JP JP2022528249A patent/JP7670705B2/ja active Active
- 2020-11-20 WO PCT/EP2020/082888 patent/WO2021099572A1/en not_active Ceased
- 2020-11-20 MX MX2022005601A patent/MX2022005601A/es unknown
- 2020-11-20 CN CN202080092410.7A patent/CN114929268A/zh active Pending
- 2020-11-20 BR BR112022009797A patent/BR112022009797A2/pt unknown
- 2020-11-20 AU AU2020388973A patent/AU2020388973A1/en active Pending
- 2020-11-20 US US17/778,398 patent/US20230059344A1/en active Pending
- 2020-11-20 CA CA3159666A patent/CA3159666A1/en active Pending
- 2020-11-20 KR KR1020227020948A patent/KR20220116191A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022005601A (es) | 2022-08-15 |
| JP2023503858A (ja) | 2023-02-01 |
| EP4061404A1 (en) | 2022-09-28 |
| CA3159666A1 (en) | 2021-05-27 |
| KR20220116191A (ko) | 2022-08-22 |
| WO2021099572A1 (en) | 2021-05-27 |
| IL293012A (en) | 2022-07-01 |
| CN114929268A (zh) | 2022-08-19 |
| AU2020388973A1 (en) | 2022-05-26 |
| JP7670705B2 (ja) | 2025-04-30 |
| US20230059344A1 (en) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009797A2 (pt) | Usos médicos de vaccinia vírus ankara modificado (mva) recombinante com coadjuvante de 4-1bbl | |
| BR112014028684A2 (pt) | subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos | |
| BRPI1007743A2 (pt) | Linhagens de célula aviária imortalizada, usos de uma linhagem de célula aviária imortalizada, métodos para a produção de vírus e métodos para a produção de proteína | |
| BR112015003109A2 (pt) | Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2. | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112022007612A2 (pt) | Inibidores de raf quinases | |
| NO20074824L (no) | Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter | |
| SV2006002134A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv | |
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| CO6382139A2 (es) | Anticuerpo anti-cmet novedoso | |
| BR112018000632A2 (pt) | moléculas de anticorpo que ligam a cd79 | |
| CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| BR112018069515A2 (pt) | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica | |
| BR112012022552A8 (pt) | uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0721137B8 (pt) | compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos. | |
| NO20084396L (no) | Kombinasjonsterapi | |
| CL2008002537A1 (es) | Compuestos derivados de acido 6-fenil-nicotinico, con actividad moduladora de ppar-alfa; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar y/o prevenir dislipidemias, arteriosclerosis e insuficiencia cardiaca. | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| BRPI0913291A2 (pt) | composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto | |
| BR112015002357A2 (pt) | compostos e composições ativadores de enzimas | |
| BR112022026521A2 (pt) | Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renal | |
| BR112022001229A2 (pt) | Polipeptídeos tendo efeitos antissenescentes e usos dos mesmos | |
| BR112014024220A2 (pt) | genes que codificam celulase | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares |